Your browser is no longer supported. Please, upgrade your browser.
Settings
CYT [NASD]
Cyteir Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own18.00% Shs Outstand32.48M Perf Week25.24%
Market Cap625.24M Forward P/E- EPS next Y-1.75 Insider Trans0.00% Shs Float2.17M Perf Month-10.05%
Income-22.20M PEG- EPS next Q-1.46 Inst Own38.40% Short Float24.39% Perf Quarter-
Sales- P/S- EPS this Y-38.40% Inst Trans- Short Ratio2.63 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh2.59 P/C7.43 EPS next 5Y38.00% ROE- 52W Range14.00 - 23.10 Perf YTD10.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.67% Beta-
Dividend %- Quick Ratio20.00 Sales past 5Y- Gross Margin- 52W Low37.50% ATR1.87
Employees31 Current Ratio20.00 Sales Q/Q- Oper. Margin- RSI (14)57.93 Volatility11.55% 9.62%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.88 Prev Close18.14
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume201.29K Price19.25
Recom- SMA208.40% SMA506.58% SMA2006.58% Volume178,029 Change6.12%
Jul-13-21Initiated Wedbush Outperform $40
Jul-13-21Initiated Morgan Stanley Overweight $33
Jul-13-21Initiated JP Morgan Overweight $30
Jul-13-21Initiated BofA Securities Buy $23
Jun-22-21 05:00PM  
Jun-17-21 07:15PM  
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.